Moleculent Raises $20M to Scale Functional Profiling Platform, Accelerate US Expansion

Moleculent has announced the closing of a $20 million financing round that supports its mission to pioneer functional profiling. Namely, the capital will go toward expansion of Moleculent’s Techstart Early Access Program, supporting commercial launch of the company’s instrument.

Moreover, the funding—Rubicon Healthcare Partners leading, with Arch Venture Partners, Eir Ventures, and others—accelerates United States commercial operations. Moleculent’s vision is to use functional profiling to map cell-cell communication at scale in human tissue.

How Functional Profiling Works

Moleculent’s technology is based on a proprietary proximity litigation assay, which detects cell-cell interactions in their native environments at high-plex. The platform accordingly enables cell typing through detection of individual proteins, which provides tissue context.

The automated instrument Moleculent is developing has the potential to enable large-scale studies with high reproducibility and minimal hands-on time.

Olle Ericsson, PhD, Moleculent Co-Founder and CEO, said the aim is to make the technology globally available to translational labs.

“The market is telling us it’s ready,” Ericsson said. “We are seeing surging demand from leading research institutions and pharmaceutical partners across both Europe and the U.S. … This new funding allows us to move more aggressively.”

The Techstart Early Access Program gives certain academic and biopharmaceutical partners priority access to the platform ahead of commercial launch.

New Member of Moleculent Board

Ole Dahlberg, Managing Partner at Rubicon, will join Moleculent’s board of directors as a condition of the financing.

“We have evaluated platforms across the life sciences tools landscape for years,” Dahlberg said. “Moleculent stands out as truly category-defining. The company’s approach to directly mapping cell-cell communication has the potential to transform how researchers study disease and develop therapies.”